News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
-- Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments -- CAMBRIDGE, Mass. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024
-- Chief executive officer purchases approximately $2 million of shares of Sarepta’s common stock -- CAMBRIDGE, Mass. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision
View HTML
Toggle Summary Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024
Chief executive officer indicates interest in purchasing $2 million of shares of Sarepta's common stock CAMBRIDGE, MA -- (Marketwired) -- 11/07/17 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) , a commercial-stage biopharmaceutical company focused on the discovery and development of precision
View HTML
Toggle Summary Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
-- Sarepta to immediately initiate a Phase 1/2a clinical trial in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51 -- CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on
View HTML
Toggle Summary Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
-- Nationwide Children’s Hospital to initiate a Phase 1/2a clinical trial at potentially therapeutic doses in children with DMD by mid-November 2017 -- -- First micro-dystrophin gene therapy program in clinical development for DMD -- CAMBRIDGE, Mass. , Nov.
View HTML
Toggle Summary Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program
-- Nationwide Children’s Hospital is on track to initiate a Phase 1/2a clinical trial in individuals with Duchenne muscular dystrophy (DMD) by year-end 2017 -- CAMBRIDGE, Mass. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company
View HTML
Toggle Summary Sarepta Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on October 31, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR/Cas9 Technology to Develop New Treatments for Duchenne Muscular Dystrophy (DMD)
-- Exclusive license option grants Sarepta rights to Duke intellectual property for CRISPR/Cas9 -- CAMBRIDGE, Mass. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision
View HTML
Toggle Summary Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments
-- Third quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $46 million -- -- Company raises annual 2017 revenue guidance to between $150 million and $155 million -- CAMBRIDGE, Mass. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.